Limits...
Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

View Article: PubMed Central - PubMed

ABSTRACT

Background: The primary objective of this study was to assess the efficacy, under field conditions, of a novel ready-to use Mycoplasma hyopneumoniae (M hyo) and Porcine circovirus type 2 (PCV2) combination vaccine given to piglets as one vaccination (1-shot) at 3 weeks of age. The study was carried out according to a controlled, randomised, and blinded design in a Greek pig herd with clinical M. hyo and subclinical PCV2 infection. Moreover, based on serology at the time of vaccination, the average PCV2 titre was 9.15 log2 and represented the level of maternally derived antibodies (MDA). In total 602 healthy suckling piglets, originating from 4 weekly farrowing batches were allocated randomly, within litters, to one of two groups. The pigs in one group were vaccinated with the test product and the other pigs were injected with saline.

Results: Vaccination significantly reduced lesions of craneo-ventral pulmonary consolidation in vaccinated group [expressed as lung lesion score (LLS)] (Mixed model ANOVA: p < 0.0001). The mean LLS was 17.1 in the controls and 10.6 in the treatment group, respectively. The average daily weight gain (ADWG) during the finishing (54 g better in the treatment group) and whole study period (34 g better in vaccinated animals) was significantly greater in vaccinated than control pigs. The vaccinated pigs had a significant reduction of PCV2 viraemia when compared with the controls.

Conclusions: The test product was considered effective in the face of average MDA, based on significantly reduced severity of LLS and PCV2 viral load, as well as improved ADWG in vaccinated versus control pigs.

No MeSH data available.


PCV2 serological results, by vaccination group and week of age legend: Statistical differences levels: Week 3: p = 0.9162, Week 6 p = 0.3069, Week 10 p < 0.0001, Week 14 p < 0.0001, Week 18 p = 0.0013, Week 22 p < 0.0001
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5382375&req=5

Fig2: PCV2 serological results, by vaccination group and week of age legend: Statistical differences levels: Week 3: p = 0.9162, Week 6 p = 0.3069, Week 10 p < 0.0001, Week 14 p < 0.0001, Week 18 p = 0.0013, Week 22 p < 0.0001

Mentions: The mean antibody titres against PCV2 in both groups increased between 18 and 22 weeks of the study, indicating a field infection during the finishing period. The titres in the vaccinated group were higher than in the controls from 6 weeks until the end of the study. The results are summarised in Fig. 2. Statistically significant differences were observed in samples from weeks 10, 14, 18 and 22 (p < 0.0001, p < 0.0001, p = 0.0013, and p < 0.0001, respectively).Fig. 2


Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm
PCV2 serological results, by vaccination group and week of age legend: Statistical differences levels: Week 3: p = 0.9162, Week 6 p = 0.3069, Week 10 p < 0.0001, Week 14 p < 0.0001, Week 18 p = 0.0013, Week 22 p < 0.0001
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5382375&req=5

Fig2: PCV2 serological results, by vaccination group and week of age legend: Statistical differences levels: Week 3: p = 0.9162, Week 6 p = 0.3069, Week 10 p < 0.0001, Week 14 p < 0.0001, Week 18 p = 0.0013, Week 22 p < 0.0001
Mentions: The mean antibody titres against PCV2 in both groups increased between 18 and 22 weeks of the study, indicating a field infection during the finishing period. The titres in the vaccinated group were higher than in the controls from 6 weeks until the end of the study. The results are summarised in Fig. 2. Statistically significant differences were observed in samples from weeks 10, 14, 18 and 22 (p < 0.0001, p < 0.0001, p = 0.0013, and p < 0.0001, respectively).Fig. 2

View Article: PubMed Central - PubMed

ABSTRACT

Background: The primary objective of this study was to assess the efficacy, under field conditions, of a novel ready-to use Mycoplasma hyopneumoniae (M hyo) and Porcine circovirus type 2 (PCV2) combination vaccine given to piglets as one vaccination (1-shot) at 3&nbsp;weeks of age. The study was carried out according to a controlled, randomised, and blinded design in a Greek pig herd with clinical M. hyo and subclinical PCV2 infection. Moreover, based on serology at the time of vaccination, the average PCV2 titre was 9.15 log2 and represented the level of maternally derived antibodies (MDA). In total 602 healthy suckling piglets, originating from 4 weekly farrowing batches were allocated randomly, within litters, to one of two groups. The pigs in one group were vaccinated with the test product and the other pigs were injected with saline.

Results: Vaccination significantly reduced lesions of craneo-ventral pulmonary consolidation in vaccinated group [expressed as lung lesion score (LLS)] (Mixed model ANOVA: p&thinsp;&lt;&thinsp;0.0001). The mean LLS was 17.1 in the controls and 10.6 in the treatment group, respectively. The average daily weight gain (ADWG) during the finishing (54&nbsp;g better in the treatment group) and whole study period (34&nbsp;g better in vaccinated animals) was significantly greater in vaccinated than control pigs. The vaccinated pigs had a significant reduction of PCV2 viraemia when compared with the controls.

Conclusions: The test product was considered effective in the face of average MDA, based on significantly reduced severity of LLS and PCV2 viral load, as well as improved ADWG in vaccinated versus control pigs.

No MeSH data available.